If there is one thing that differentiates Clay Siegall from others in the corporate world it would be the fact that he is not afraid to take a stand for what he believes in. His blog is proof positive of that, and offers a number of examples.
First of all, it demonstrates that he is not just interested in eradicating cancer through top-notch research. The blog illustrates a world citizen who shows concern about those around him. His most recent posts show he is concerned about our current president’s decision to withdraw from the world climate change agreement. Some of his posts show that he is not afraid to take an “out of the box” viewpoint on things either. This would include his post regarding how recycling simply causes people just to waste more. Other posts show an interest in astronomy, brain science, the financial markets, and even meteorology.
Of course, to say that Clay Siegall is also dedicated to preventing cancer in as many people as possible would be an understatement. The man was instrumental in co-founding Seattle Genetics in 1998 and has effectively led the company into the 21st Century with a number of critical victories under his belt.
First of all, Siegall and his associates developed ADCETRIS, which secured FDA approval in 2011. ADCETRIS was widely accepted as one of the first antibody-drug conjugates to be introduced in order to help cancer patients with their weakened immune systems. It is often not the cancer that kills the patient, but it is their weakened immune system that they succumb to.
Since this drug finally reached FDA approval in 2011, it has now helped literally millions of cancer patients worldwide in over 60 countries. Dr. Siegall is truly a rare combination: an individual who has an extensive cancer knowledge but who also has the leadership acumen to make these scientific advances come to fruition.
If a true cure for cancer is ever discovered, it will come from the dedication of men such as Dr. Siegall. And if he has anything to do with it, that cure will come sooner rather than later.